Table 2. Company, Drug Name, and Speaker Information From PCNSDACa.
| Drug | Company | Date of Meeting | No. of Speakers | People Who Spoke Positively/Total Who Disclosed a COI (%) | People Who Spoke Positively/Total With the Disease (%) | People Who Spoke Positively/Total Who Took the Drug (%) |
|---|---|---|---|---|---|---|
| Corticotropin injection (Acthar) | Questcor Pharmaceuticals | 5/6/10 | 20 | 15/15 (100) | 2/2 (100) | 2/2 (100) |
| Ataluren | PTC Therapeutics Inc | 9/28/17 | 29 | 26/26 (100) | 6/6 (100) | 6/6 (100) |
| Drisapersen | BioMarin Pharmaceutical Inc | 11/24/15 | 24 | 16/18 (88.9) | 2/2 (100) | 2/2 (100) |
| Etelpirsen | Sarepta Therapeutics Inc | 4/25/16 | 52 | 30/30 (100) | 7/7 (100) | 7/7 (100) |
| Ezogabine (Potiga) | Valeant Pharmaceuticals | 8/11/10 | 1 | 0/0 | 0/0 | 0/0 |
| Fampridine (Ampriva) | Acorda Therapeutics Inc | 10/14/09 | 11 | 5/5 (100) | 5/6 (83.3) | 3/3 (100) |
| Fingolimod | Novartis Pharmaceuticals Corporation | 6/10/10 | 6 | 1/1 (100) | 4/4 (100) | 2/2 (100) |
| Luflupane (DaTSCAN) | GE HealthCare | 8/11/09 | 3 | 3/3 (100) | 0/0 | 0/0 |
| Lamictal XR | SmithKline Beecham Corporation | 3/10/11 | 1 | 1/1 (100) | 0/0 | 0/0 |
| Lemtrada | Genzyme Corporation | 11/13/13 | 10 | 5/5 (100) | 8/8 (100) | 6/6 (100) |
| Phenytoin-fosphenytoin | Pfizer Inc | 11/3/10 | 1 | 1/1 (100) | 0/0 | 0/0 |
| Florbetapir | Avid Radiopharmaceuticals | 1/20/11 | 8 | 3/4 (75) | 0/0 | 0/0 |
| Rasagiline (Azilect) | Teva Neuroscience Inc | 10/17/11 | 7 | 4/4 (100) | 1/1 (100) | 1/1 (100) |
| Suvorexant | Merck Sharp & Dohme Corp | 5/22/13 | 3 | 1/1 (100) | 0/0 | 0/0 |
| Tafamidis meglumine (Vyndaqel) | FoldRx Pharmaceuticals, Inc | 5/24/12 | 15 | 2/2 (100) | 8/8 (100) | 1/1 (100) |
| Tasimelteon (Hetlioz) | Vanda Pharmaceuticals Inc | 11/14/13 | 11 | 7/8 (87.5) | 3/4 (75) | 1/1 (100) |
| Vigabatrin | Ovation Pharmaceuticals | 1/7-8/09 | 24 | 5/5 (100) | 2/2 (100) | 1/1 (100) |
| Total | NA | NA | 226 | 125/129 (96.9) | 48/50 (96.0) | 32/32 (100) |
Abbreviations: NA, not applicable; PCNSDAC, Peripheral and Central Nervous System Drug Advisory Committee.
a
Some speakers declared a conflict of interest, had the disease, and took the drug and may be counted more than once in the last 3 columns.